

Partnering within our communities to provide solutions for better health

P.O. Box 5119, Helena, MT 59604 Phone 406.443.6002. Toll-Free 1.800.395.7961 Fax 406.513.1928 . Toll-Free 1.800.294.1350

## $\begin{tabular}{ll} Montana \ Healthcare \ Programs \ Prior \ Authorization \ Request \ Form \ for \ Use \ of \\ Xolair^{TM} \ (omalizumab) \end{tabular}$

	Member Name:	DOB:	Date:	
-	Medicaid ID:	Prescriber Phone	<b>:</b>	
-	Prescriber Name/Specialty:	Prescriber Fax:		
-	Requested Dose/Directions:			
P	lease complete below information for applicable situation	, <u>Initiation</u> or <u>Contin</u>	uation of therapy:	
Ple	ease check appropriate diagnosis and complete correspondi	ing information:		
1. [	☐ <u>Allergic Asthma:</u>			
	a. Prescriber practices in one of the following specialty	clinics:   Allergy	□ Pulmonology □ Immunology	
	• Action Required: If not in specialty clinic, inf	Formation on annual co	onsult with an appropriate specialist	
	is required: Name:	Contact I	Date:	
	b. Member must be 6 years of age or older <b>AND</b> have as	sthma and allergies: □	] Yes □ No	
	c. Member must be adherent to ICS therapy for at least 3	3 consecutive months:	:	
	Please list current ICS therapy:			
	d. Prescriber must submit <b>BOTH</b> a pretreatment serum	total IgE level:	and current body weight:	
	e. Initial authorization will be granted for 1 year			
2.	☐ Chronic Idiopathic Urticaria (CIU):			
	b. Prescriber practices in one of the following specialty	clinics:   Allergy	☐ Dermatology ☐ Immunology	
	• Action Required: If not in specialty clinic, information on annual consult with an appropriate specialist			
	is required: Name:	Contact I	Date:	
	b. Member must be 12 years of age or older <b>AND</b> have a	a diagnosis of chronic	idiopathic urticaria: ☐ Yes ☐ No	

	c.	Member must have had an inadequate response to 2 different H <sub>1</sub> antihistamine trials of 4 weeks each.		
		1. Drug name: Date/Duration of use:		
		2. Drug name: Date/Duration of use:		
	d.	Initial authorization will be granted for 3 months		
3.		Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP):		
	a. Member is 18 years of age or older: ☐ Yes ☐ No			
	b.	<ul> <li>b. Medication is prescribed by, or in consultation, with: □ Allergist □ Immunologist □ Otolaryngologist</li> <li>• Action Required: If not in a specialty clinic, information on annual consult with an appropriate</li> </ul>		
		specialist is required: Name: Contact Date:		
	c.	Member has clinical documentation of chronic rhinosinusitis WITH nasal polyps as evidenced by CT scan or endoscopy: ☐ Yes ☐ No		
	d.	d. Member must have had an inadequate treatment response, intolerance, or contraindication to <u>both</u> of the		
		following:		
		1. <b>One</b> different intranasal corticosteroids*:		
		> Name:Dates:		
		*Note: Must have been adherent to therapy at optimized doses for at least <u>3</u> months.		
		2. Systemic corticosteroid trial (must be within last year): Name: Dates: Dates:		
	e.	Member will concurrently use an intranasal corticosteroid: ☐ Yes ☐ No - contraindicated in member		
	f.	Provider must include the pretreatment serum total IgE level and current body weight for dose		
		calculation/verification: IgE level: Weight:		
		*Maximum dose allowed is 600mg every 2 weeks – please refer to package insert for dosing guide.		
	g.	Initial authorization will be granted for 6 months		
CO	)NT	INUATION OF THERAPY:		
	1.	Member has been adherent to therapy: ☐ Yes ☐ No (will be verified through claims history)		
	2.	Annual specialist consult attached if prescriber is not a specialist. ☐ Yes ☐ No ☐ N/A prescriber is specialist		
	3.	(Applies only to CRSwNP therapy) Member has been adherent to concurrent intranasal corticosteroids:		

**3.** 

□ Yes □ No		
4. Documentation is attached supporting positive response to therapy as demonstrated by a reduction in the frequency and/or severity of symptoms: ☐ Yes ☐ No		
Reauthorization will be issued for 1 year for Allergic Asthma and Nasal Polyps or for 6 months for CIU.		
Please complete form, including required attachments and fax to: Drug Prior Authorization Unit @ 1-800-294-1350		

9/2021